In addition to HER2 overexpression discussed in breast, gastric and colorectal cancer, activating HER2 mutations are found in multiple solid tumors and are potentially drug-able [144], but no approvals have occurred to date. This evidence concerns the gene ERBB2 and colorectal cancer.